Cna Financial Corp Ascendis Pharma A/S Transaction History

Cna Financial Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$84.03 - $110.23 $27,729 - $36,375	-330 Reduced 9.95%	2,985 $308,000
Q1 2022 May 10, 2022	SELL	$102.18 - $135.75 $25,647 - $34,073	-251 Reduced 7.04%	3,315 $389,000
Q4 2021 Feb 11, 2022	BUY	$127.1 - $169.66 $64,821 - $86,526	510 Added 16.69%	3,566 $480,000
Q3 2021 Nov 12, 2021	SELL	$112.67 - $176.92 $16,224 - $25,476	-144 Reduced 4.5%	3,056 $487,000
Q2 2021 Aug 12, 2021	BUY	$121.62 - $145.29 $49,864 - $59,568	410 Added 14.7%	3,200 $421,000
Q1 2021 May 14, 2021	BUY	$124.92 - $173.33 $9,993 - $13,866	80 Added 2.95%	2,790 $360,000
Q4 2020 Feb 12, 2021	BUY	$151.2 - $182.76 $7,559 - $9,138	50 Added 1.88%	2,710 $452,000
Q3 2020 Nov 12, 2020	BUY	$134.29 - $154.32 $28,200 - $32,407	210 Added 8.57%	2,660 $410,000
Q2 2020 Aug 13, 2020	BUY	$110.87 - $156.01 $271,631 - $382,224	2,450 New	2,450 $362,000

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.